eligibility_summary
Eligibility: Must have previously received Equecabtagene Autoleucel Injection, if from pre/post-marketing studies, must have completed or withdrawn, must provide ethics-approved informed consent. Exclude: received any other lentiviral vector cell/gene therapy (commercial or investigational) between Equecabtagene infusion and consent.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: Equecabtagene autoleucel (Eque-cel), an autologous BCMA-directed CAR-T cell gene therapy (lentiviral-transduced patient T cells). Mechanism: engineered T cells express a chimeric antigen receptor that binds B-cell maturation antigen (BCMA/TNFRSF17) on malignant plasma cells, inducing CAR-mediated T-cell activation, clonal expansion, cytokine release, and perforin/granzyme-dependent cytotoxic killing of BCMA+ myeloma cells, CAR-T cells may persist long term due to genomic integration. Study: observational, no new treatment—long-term follow-up of prior Eque-cel recipients to assess safety, efficacy, CAR-T persistence, and integration-related risks. Targets: BCMA on plasma cells. Pathways: CAR/TCR signaling, downstream cytokine signaling, and cytolytic effector pathways. Condition: multiple myeloma.